Industry ยท Oct 2026
Biotechnology stocks ranked by gap to the model's fair value
Faircurve's model values 31 biotechnology stocks. 18 of them are ranked below by the gap between the model's fair value and the last close, as of 31 Oct 2026: 5 read as Undervalued, 12 as Fairly valued and 1 as Overvalued. The median gap across the ranked names is +1.5%. The widest gaps above the price are BMRN (+26.5%), KRYS (+25.9%), FTRE (+24.3%). The widest below it are MRNA (-15.0%), RCUS (-13.1%), PTCT (-12.3%).
Valuations as of . Prices are the closes of 3 Nov 2026. The gap is the model's fair value against the price: a positive gap means the fair value is above the price. It states what the model concluded, not where the price goes next.
The ranking
| Rank | Company | Last close | Model fair value | Gap | Model verdict | Quality score | Market value |
|---|---|---|---|---|---|---|---|
| 1 | BMRN BioMarin Pharmaceutical Inc. | $55.66 | $70.40 | +26.5% | Undervalued | 56 | $11.3B |
| 2 | KRYS Krystal Biotech, Inc. | $305.03 | $384.08 | +25.9% | Undervalued | 81 | $9.8B |
| 3 | FTRE Fortrea Holdings Inc. | $20.95 | $26.04 | +24.3% | Undervalued | 41 | $2.0B |
| 4 | INCY Incyte Corporation | $117.59 | $141.04 | +19.9% | Undervalued | 70 | $24.4B |
| 5 | ADMA ADMA Biologics, Inc. | $11.11 | $13.32 | +19.9% | Undervalued | 67 | $2.6B |
| 6 | VCEL Vericel Corporation | $41.09 | $46.61 | +13.4% | Fairly valued | 65 | $2.1B |
| 7 | VIR Vir Biotechnology, Inc. | $11.22 | $12.12 | +8.0% | Fairly valued | 42 | $1.9B |
| 8 | UTHR United Therapeutics Corporation | $601.32 | $634.32 | +5.5% | Fairly valued | 66 | $25.7B |
| 9 | INSM Insmed Incorporated | $104.44 | $106.20 | +1.7% | Fairly valued | 46 | $24.6B |
| 10 | REGN Regeneron Pharmaceuticals, Inc. | $973.36 | $985.42 | +1.2% | Fairly valued | 51 | $95.5B |
| 11 | NBIX Neurocrine Biosciences, Inc. | $164.85 | $162.09 | -1.7% | Fairly valued | 68 | $14.9B |
| 12 | ROIV Roivant Sciences Ltd. | $36.04 | $34.62 | -3.9% | Fairly valued | 18 | $26.7B |
| 13 | VRTX Vertex Pharmaceuticals Incorporated | $530.76 | $504.07 | -5.0% | Fairly valued | 62 | $141.7B |
| 14 | EXEL Exelixis, Inc. | $72.31 | $68.28 | -5.6% | Fairly valued | 73 | $17.4B |
| 15 | TECH Bio-Techne Corporation | $72.66 | $64.04 | -11.9% | Fairly valued | 55 | $11.4B |
| 16 | PTCT PTC Therapeutics, Inc. | $68.12 | $59.76 | -12.3% | Fairly valued | 37 | $5.0B |
| 17 | RCUS Arcus Biosciences, Inc. | $18.91 | $16.43 | -13.1% | Fairly valued | 31 | $2.3B |
| 18 | MRNA Moderna, Inc. | $228.44 | $194.13 | -15.0% | Overvalued | 34 | $88.5B |
The Global Pulse
Faircurve's market note, in your inbox each market day
The Global Pulse is Faircurve's note after each US session: what moved, in plain words. No account needed.
Valued but not ranked
These 13 names are valued but not ranked, for one of four reasons: the model grades the evidence as low or has not graded it yet, the inputs are under review, the gap is wider than 60%, or the valuation is more than three weeks old. The numbers are shown for reference.
| Company | Last close | Model fair value | Gap | Why it is not ranked | Quality score | Market value |
|---|---|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals Inc. | $20.57 | $20.65 | +0.4% | Low evidence grade | $3.5B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $159.89 | $165.50 | +3.5% | Low evidence grade | $22.1B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $59.53 | $49.37 | -17.1% | Data under review | 49 | $8.5B |
| CYTK Cytokinetics, Incorporated | $62.31 | $52.67 | -15.5% | Low evidence grade | 50 | $8.8B |
| HALO Halozyme Therapeutics, Inc. | $128.62 | $134.12 | +4.3% | Low evidence grade | 82 | $14.9B |
| HRMY Harmony Biosciences Holdings, Inc. | $37.02 | $38.98 | +5.3% | Low evidence grade | $2.3B | |
| INVA Innoviva, Inc. | $20.93 | $22.92 | +9.5% | Low evidence grade | 63 | $1.5B |
| JAZZ Jazz Pharmaceuticals plc | $229.74 | $256.45 | +11.6% | Low evidence grade | 64 | $14.0B |
| LGND Ligand Pharmaceuticals Incorporated | $313.52 | $297.44 | -5.1% | Low evidence grade | 47 | $6.4B |
| PTGX Protagonist Therapeutics, Inc. | $140.24 | $167.40 | +19.4% | Low evidence grade | 63 | $9.4B |
| SRPT Sarepta Therapeutics, Inc. | $18.54 | $22.32 | +20.4% | Low evidence grade | 49 | $2.0B |
| TGTX TG Therapeutics, Inc. | $60.75 | $70.94 | +16.8% | Low evidence grade | 56 | $9.4B |
| XNCR Xencor, Inc. | $30.64 | $33.00 | +7.7% | Data under review | 37 | $2.2B |